High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneTelomerase: The Devil InsideMulti-OMICs and Genome Editing Perspectives on Liver Cancer Signaling NetworksMolecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesTelomeres, NAFLD and Chronic Liver DiseaseCancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesisReactivation of telomerase in cancerVariations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancerThe mutational landscape of hepatocellular carcinomaCurrent Proceedings in the Molecular Dissection of Hepatocellular Adenomas: Review and Hands-on Guide for DiagnosisViruses in cancer cell plasticity: the role of hepatitis C virus in hepatocellular carcinomaGenetic alterations in hepatocellular carcinoma: An updateβ-Catenin Signaling and Roles in Liver Homeostasis, Injury, and TumorigenesisMolecular Markers in Low-Grade Glioma-Toward Tumor ReclassificationA Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma CellsGenetic variants in TERT are associated with risk of gastric cancer in a Chinese Han populationComparison of hepatocellular carcinoma in Eastern versus Western populations.Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.Age, hepatitis C virus infection, and the risk of cancer: Unlocking a complex puzzle of interactions.TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entitiesPhase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Telomere biology and translational research.The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.Promoter mutations and cellular distribution of telomerase in non-clear cell and clear cell hepatocellular carcinoma.Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma.Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care.Identification of drivers from cancer genome diversity in hepatocellular carcinoma.Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis.Telomere-regulating genes and the telomere interactome in familial cancers.Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis modelTelomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.Hepatocellular carcinoma: clinical frontiers and perspectives.siRNA suppression of hTERT using activatable cell-penetrating peptides in hepatoma cells.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Quantitative Fitness Analysis Identifies exo1∆ and Other Suppressors or Enhancers of Telomere Defects in Schizosaccharomyces pombe.
P2860
Q27555640-63A88945-E96B-4B50-BEAC-E07E4DCCF21AQ54749093-84E96F68-EB48-4ED7-A084-7CC4E0B0242CQ54881504-1C7D61D9-3668-4DCF-85BA-02375BD4FA47Q54881505-C2006B55-B67B-4D4F-A2CE-800B9A0EACE3Q54882746-F49BA46F-ADF5-4121-AD79-8A74FA01E382Q54882834-F189DE9F-9183-4884-8B0E-B04F8EFE9889Q54889847-EACB458C-FE5B-4217-9B92-91993ED0E6C6Q54889850-5BB0F1E3-B791-4397-8CA8-D4DCD7AAB252Q54896848-C3AE995D-2AAE-4559-AC2E-892D3931977EQ54902491-255165BA-A692-478D-BC3A-4F6D08D81767Q54903975-BF15E555-2B46-4165-8D9E-2BE75E880518Q54947574-D32B3C14-DF3D-430E-B88B-C3DED3625B0EQ54953666-D9740BD8-C913-46B0-AD1B-F47726F798AAQ54955141-317AF1B2-B2AB-4958-A4CE-7F7652956407Q54955183-17D91E41-3A40-48E5-A304-078C4B8E85A3Q54955184-CAA4E102-1BA4-4192-9365-BECF34DE349CQ54955197-8DE7F5BD-FEE4-4C6A-B04E-21C475D6FF82Q54955201-1DD47626-8F91-4B1C-AC45-A624310B504FQ54955204-E6E95CCF-1BCE-4F0A-87B2-71EC94ED57B6Q54972310-4B3CB60D-9AC3-4ABB-AC86-B50445AB7AEAQ54972311-CCB12240-A7ED-4310-BF9B-D7580F48D1F2Q5731621-C3B6F026-7A75-4254-8E5C-3C3E906FBCFA
P1343
Q26738705-4773F23A-A121-49E1-92CF-E978DDB2169EQ26739925-981F40CA-2A01-4CCB-8064-4C3D70DAEB99Q26739948-8152697B-E456-4454-9831-BC27C79B9F94Q26741086-C46A723D-3993-4F4E-9802-4A557B960267Q26745338-E0E6EE7A-839F-4F13-B810-3A8BB248A881Q26753037-5ED9CC56-711D-4A61-93D6-A330A87CE442Q26766386-90422C17-75C5-4927-9F7C-AEF1AEA29DB8Q26769014-1FF369CC-D35A-44A9-A534-02D510E82316Q26775381-A70CDC09-DF2B-40FC-8529-80F2F5819FF6Q26777478-5EFD3AA2-ED7F-4D40-8CB9-C5F3FCA44967Q26781373-D4146C51-1A5A-4F25-B61A-14B534AAA4FDQ27012614-F4E76A4E-1B7D-4C95-88D5-6538A8E407C3Q28073241-F5AA0610-1AF3-4099-98EA-8D6D70110ACFQ28087660-01D2CC67-CBFD-48BE-BC4C-29669918C5C5Q28383205-D87AF619-75B0-464F-A934-A940C7472860Q28553513-67F895F7-761D-4282-BBBA-95FA2BD1671CQ29248191-1AE4EBE5-D91B-40B2-9E77-AF8EDBEFDB58Q30245396-01539A6D-A5CF-4FB2-BAFB-6DBC01A3FC90Q30459452-B451D798-7D48-432C-8E20-BAA1FCFB99C4Q33364626-47155740-6A64-4894-9568-35680DDCA701Q33414576-A4ED503B-D8EE-48A2-AFDD-36B9F9DFE38BQ33422258-3019B1FB-9F5B-4AB0-A60D-54633FE42607Q33613946-060B59DD-48B6-4D8A-BF3E-CAC564E0AC06Q33618591-3C0E62D2-4CB7-4844-B6EF-B18DE7555CB0Q33688439-8D764787-7E62-4174-A93D-118D7A48FAE9Q33688632-9829EDF6-21EE-4777-B00A-1E1625D39FB8Q33706203-66D2EF8E-CCA0-4E63-A4E9-FE174A621150Q33833379-96A6A399-58E6-4AAE-BF82-B62B5F85EC91Q33907993-B8B710C0-4DD7-4F7A-AF75-A5E2FDD26E06Q33926379-CD87CE5C-0BC0-49C9-BB8E-F26C3D46A695Q34499685-3D212059-06BB-4ABA-889E-1907F9AC9A81Q34619389-181B3055-51AB-4827-9E5A-8A990CBEDB2EQ34784471-F8ECDF93-22C4-4B92-A17A-FFAEAC8FF4E2Q34827556-1EAEA2E4-B8F7-45C7-B5C8-FEF0F183C2F1Q34989670-964014C4-76FF-4322-879A-456C4DFB3E2CQ35024614-0280A8E7-463A-4765-811E-3693CC627CEBQ35112053-8008B71B-3D66-4DB8-8705-654C8FBCD370Q35207239-19C36577-089B-4CE4-B375-0AD39FDE326FQ35619104-58EFD710-0AD9-4C62-B84B-531F02C30FEBQ35689663-907E672D-F399-4230-B9F6-DDFE9350458E
P2860
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High frequency of telomerase r ...... noma and preneoplastic lesions
@en
High frequency of telomerase r ...... oma and preneoplastic lesions.
@nl
type
label
High frequency of telomerase r ...... noma and preneoplastic lesions
@en
High frequency of telomerase r ...... oma and preneoplastic lesions.
@nl
prefLabel
High frequency of telomerase r ...... noma and preneoplastic lesions
@en
High frequency of telomerase r ...... oma and preneoplastic lesions.
@nl
P2093
P2860
P4510
P50
P356
P1476
High frequency of telomerase r ...... noma and preneoplastic lesions
@en
P2093
Charles Balabaud
Christophe Laurent
Daniel Cherqui
Julien Calderaro
Maxime Mallet
P2860
P2888
P356
10.1038/NCOMMS3218
P407
P577
2013-01-01T00:00:00Z
P5875
P6179
1021618987